Clinical Trial Update: Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial assessing the safety of combining sintilimab with XELOX (capecitabine + oxaliplatin) and bevacizumab as neoadjuvant therapy in patients with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer with Liver Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer Metastatic | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING